Trial Outcomes & Findings for Study Evaluating Neratinib In Combination With Vinorelbine In Subjects With Advanced Or Metastatic Solid Tumors (NCT NCT00958724)

NCT ID: NCT00958724

Last Updated: 2018-06-28

Results Overview

Number of participants experiencing DLT of neratinib in combination with vinorelbine in Japanese patients.

Recruitment status

COMPLETED

Study phase

PHASE1

Target enrollment

6 participants

Primary outcome timeframe

From first dose date to 21st day

Results posted on

2018-06-28

Participant Flow

Participant milestones

Participant milestones
Measure
Nera 240 + Vino 25
Neratinib 240 mg + Vinorelbine 25 mg/m\^2
Overall Study
STARTED
6
Overall Study
COMPLETED
0
Overall Study
NOT COMPLETED
6

Reasons for withdrawal

Reasons for withdrawal
Measure
Nera 240 + Vino 25
Neratinib 240 mg + Vinorelbine 25 mg/m\^2
Overall Study
Disease Progression
6

Baseline Characteristics

Study Evaluating Neratinib In Combination With Vinorelbine In Subjects With Advanced Or Metastatic Solid Tumors

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Nera 240 + Vino 25
n=6 Participants
Neratinib 240 mg + Vinorelbine 25 mg/m\^2
Age, Categorical
<=18 years
0 Participants
n=5 Participants
Age, Categorical
Between 18 and 65 years
5 Participants
n=5 Participants
Age, Categorical
>=65 years
1 Participants
n=5 Participants
Age, Continuous
54 years
STANDARD_DEVIATION 13.37 • n=5 Participants
Sex: Female, Male
Female
4 Participants
n=5 Participants
Sex: Female, Male
Male
2 Participants
n=5 Participants
Race/Ethnicity, Customized
Japanese
6 Participants
n=5 Participants

PRIMARY outcome

Timeframe: From first dose date to 21st day

Population: Safety population

Number of participants experiencing DLT of neratinib in combination with vinorelbine in Japanese patients.

Outcome measures

Outcome measures
Measure
Nera 240 + Vino 25
n=6 Participants
Neratinib 240 mg + Vinorelbine 25 mg/m\^2
Dose Limiting Toxicity (DLT)
1 participants

SECONDARY outcome

Timeframe: From first dose date to progression or last tumor assessment, up to 40 weeks.

Population: Subjects who met eligibility criteria, received at least 2 weeks of continual daily dosing of neratinib, at least 2 doses of vinorelbine, and underwent at least 1 follow-up tumor assessment at 6 weeks, ie, approximately at cycle 2. In the case of disease progression prior to 6 weeks, a clinical assessment of progressive disease was adequate.

Best Overall Response in Evaluable Population per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.

Outcome measures

Outcome measures
Measure
Nera 240 + Vino 25
n=6 Participants
Neratinib 240 mg + Vinorelbine 25 mg/m\^2
Best Overall Response
Partial Response
1 Participants
Best Overall Response
Stable Disease >= 6 weeks
5 Participants
Best Overall Response
Stable Disease >= 24 weeks
1 Participants

SECONDARY outcome

Timeframe: From first response date to PD/death, up to 40 weeks.

Population: Subjects who had a partial or complete response

The duration of objective response was measured from the time at which measurement criteria were met for Complete Response (CR) or Partial Response (PR) (whichever status was recorded first) until the first date on which recurrence or Progressive Disease (PD) was objectively documented, taking as reference for PD the smallest measurements recorded since the treatment started.

Outcome measures

Outcome measures
Measure
Nera 240 + Vino 25
n=1 Participants
Neratinib 240 mg + Vinorelbine 25 mg/m\^2
Duration of Objective Response
12.0 weeks
Confidence Interval not estimable with only 1 subject.

SECONDARY outcome

Timeframe: From first dose date to progression or last tumor assessment, up to 40 weeks.

Population: Safety population

Proportion of subjects who achieved complete response or partial response per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.

Outcome measures

Outcome measures
Measure
Nera 240 + Vino 25
n=6 Participants
Neratinib 240 mg + Vinorelbine 25 mg/m\^2
Objective Response Rate (ORR)
16.7 percentage of participants
Interval 0.4 to 64.1

SECONDARY outcome

Timeframe: From first dose to last evaluation, up to 40 weeks.

Population: Subjects who met eligibility criteria, received at least 2 weeks of continual daily dosing of neratinib and at least 2 doses of vinorelbine, and underwent at least 1 follow-up tumor assessment at 6 weeks, i.e., approximately at cycle 2. In the case of disease progression prior to 6 weeks, a clinical assessment of PD was adequate.

Number of weeks between the date of the first dose of test article and the first date of disease recurrence or progression, or death due to any cause, was documented, censored at the last evaluation, investigator assessment. Disease Progression (PD) is defined using Response Evaluation Criteria in Solid Tumors Criteria (v1.0), at least a 20% increase in the sum of the longest diameters (LD) of target lesions, taking as reference the nadir LD, meaning the smallest sum of the LDs recorded since the treatment started; or unequivocal progression of existing nontarget lesions; or the appearance of any new lesions.

Outcome measures

Outcome measures
Measure
Nera 240 + Vino 25
n=6 Participants
Neratinib 240 mg + Vinorelbine 25 mg/m\^2
Progression Free Survival
18.2 weeks
Interval 18.0 to 24.1

SECONDARY outcome

Timeframe: Predose, and hour 1, 2, 4, 6, 8 and 24 on day 8.

Population: Population for pharmacokinetic analyses consisted of all subjects in this study who received at least 1 dose of neratinib and provided samples for pharmacokinetic assessments.

AUC of Neratinib at day 8 following administration of Neratinib 240 mg in combination with Vinorelbine 25 mg/m\^2 to Japanese Subjects with Cancer.

Outcome measures

Outcome measures
Measure
Nera 240 + Vino 25
n=5 Participants
Neratinib 240 mg + Vinorelbine 25 mg/m\^2
Area Under the Curve (AUC) Tau
1330 ng*hr/mL
Standard Deviation 925

SECONDARY outcome

Timeframe: Predose, and hour 1, 2, 4, 6, 8 and 24 on day 8.

Population: Population for pharmacokinetic analyses consisted of all subjects in this study who received at least 1 dose of neratinib and provided samples for pharmacokinetic assessments.

Terminal-phase elimination half-life of Neratinib at day 8 following Administration of Neratinib 240 mg in combination with Vinorelbine 25 mg/m\^2 to Japanese Subjects with Cancer.

Outcome measures

Outcome measures
Measure
Nera 240 + Vino 25
n=4 Participants
Neratinib 240 mg + Vinorelbine 25 mg/m\^2
Terminal-phase Elimination Half-life
14.37 hr
Standard Deviation 3.41

Adverse Events

Nera 240 + Vino 25

Serious events: 1 serious events
Other events: 6 other events
Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure
Nera 240 + Vino 25
n=6 participants at risk
Neratinib 240 mg + Vinorelbine 25 mg/m\^2
Infections and infestations
Peritoneal abscess
16.7%
1/6 • From first dose through 28 days after last dose, up to 40 weeks.

Other adverse events

Other adverse events
Measure
Nera 240 + Vino 25
n=6 participants at risk
Neratinib 240 mg + Vinorelbine 25 mg/m\^2
Blood and lymphatic system disorders
Anaemia
33.3%
2/6 • From first dose through 28 days after last dose, up to 40 weeks.
Blood and lymphatic system disorders
Leukopenia
100.0%
6/6 • From first dose through 28 days after last dose, up to 40 weeks.
Blood and lymphatic system disorders
Lymphopenia
50.0%
3/6 • From first dose through 28 days after last dose, up to 40 weeks.
Blood and lymphatic system disorders
Neutropenia
100.0%
6/6 • From first dose through 28 days after last dose, up to 40 weeks.
Cardiac disorders
Left ventricular dysfunction
16.7%
1/6 • From first dose through 28 days after last dose, up to 40 weeks.
Eye disorders
Keratitis
16.7%
1/6 • From first dose through 28 days after last dose, up to 40 weeks.
Gastrointestinal disorders
Abdominal pain
16.7%
1/6 • From first dose through 28 days after last dose, up to 40 weeks.
Gastrointestinal disorders
Abdominal pain upper
16.7%
1/6 • From first dose through 28 days after last dose, up to 40 weeks.
Gastrointestinal disorders
Diarrhoea
100.0%
6/6 • From first dose through 28 days after last dose, up to 40 weeks.
Gastrointestinal disorders
Enterocolitis
16.7%
1/6 • From first dose through 28 days after last dose, up to 40 weeks.
Gastrointestinal disorders
Gastritis
16.7%
1/6 • From first dose through 28 days after last dose, up to 40 weeks.
Gastrointestinal disorders
Nausea
66.7%
4/6 • From first dose through 28 days after last dose, up to 40 weeks.
Gastrointestinal disorders
Stomatitis
66.7%
4/6 • From first dose through 28 days after last dose, up to 40 weeks.
Gastrointestinal disorders
Vomiting
50.0%
3/6 • From first dose through 28 days after last dose, up to 40 weeks.
General disorders
Face oedema
16.7%
1/6 • From first dose through 28 days after last dose, up to 40 weeks.
General disorders
Fatigue
83.3%
5/6 • From first dose through 28 days after last dose, up to 40 weeks.
General disorders
Influenza like illness
33.3%
2/6 • From first dose through 28 days after last dose, up to 40 weeks.
General disorders
Non-cardiac chest pain
16.7%
1/6 • From first dose through 28 days after last dose, up to 40 weeks.
General disorders
Performance status decreased
16.7%
1/6 • From first dose through 28 days after last dose, up to 40 weeks.
General disorders
Pyrexia
83.3%
5/6 • From first dose through 28 days after last dose, up to 40 weeks.
Infections and infestations
Nasopharyngitis
33.3%
2/6 • From first dose through 28 days after last dose, up to 40 weeks.
Infections and infestations
Proctitis infectious
16.7%
1/6 • From first dose through 28 days after last dose, up to 40 weeks.
Injury, poisoning and procedural complications
Lumbar vertebral fracture
16.7%
1/6 • From first dose through 28 days after last dose, up to 40 weeks.
Injury, poisoning and procedural complications
Rib fracture
16.7%
1/6 • From first dose through 28 days after last dose, up to 40 weeks.
Investigations
Alanine aminotransferase increased
33.3%
2/6 • From first dose through 28 days after last dose, up to 40 weeks.
Investigations
Aspartate aminotransferase increased
16.7%
1/6 • From first dose through 28 days after last dose, up to 40 weeks.
Investigations
Blood chloride decreased
16.7%
1/6 • From first dose through 28 days after last dose, up to 40 weeks.
Investigations
Blood creatinine increased
16.7%
1/6 • From first dose through 28 days after last dose, up to 40 weeks.
Investigations
Blood lactate dehydrogenase increased
16.7%
1/6 • From first dose through 28 days after last dose, up to 40 weeks.
Investigations
Blood sodium decreased
16.7%
1/6 • From first dose through 28 days after last dose, up to 40 weeks.
Investigations
Eastern Cooperative Oncology Group performance status worsened
16.7%
1/6 • From first dose through 28 days after last dose, up to 40 weeks.
Investigations
Electrocardiogram QT prolonged
16.7%
1/6 • From first dose through 28 days after last dose, up to 40 weeks.
Investigations
Haematocrit decreased
16.7%
1/6 • From first dose through 28 days after last dose, up to 40 weeks.
Investigations
Haemoglobin decreased
33.3%
2/6 • From first dose through 28 days after last dose, up to 40 weeks.
Investigations
Monocyte count decreased
16.7%
1/6 • From first dose through 28 days after last dose, up to 40 weeks.
Investigations
Protein urine
16.7%
1/6 • From first dose through 28 days after last dose, up to 40 weeks.
Investigations
Weight decreased
50.0%
3/6 • From first dose through 28 days after last dose, up to 40 weeks.
Metabolism and nutrition disorders
Decreased appetite
83.3%
5/6 • From first dose through 28 days after last dose, up to 40 weeks.
Metabolism and nutrition disorders
Hypocalcaemia
16.7%
1/6 • From first dose through 28 days after last dose, up to 40 weeks.
Metabolism and nutrition disorders
Hypokalaemia
16.7%
1/6 • From first dose through 28 days after last dose, up to 40 weeks.
Metabolism and nutrition disorders
Hypomagnesaemia
16.7%
1/6 • From first dose through 28 days after last dose, up to 40 weeks.
Nervous system disorders
Dysgeusia
16.7%
1/6 • From first dose through 28 days after last dose, up to 40 weeks.
Nervous system disorders
Peripheral sensory neuropathy
50.0%
3/6 • From first dose through 28 days after last dose, up to 40 weeks.
Psychiatric disorders
Insomnia
33.3%
2/6 • From first dose through 28 days after last dose, up to 40 weeks.
Respiratory, thoracic and mediastinal disorders
Aspiration
16.7%
1/6 • From first dose through 28 days after last dose, up to 40 weeks.
Respiratory, thoracic and mediastinal disorders
Cough
16.7%
1/6 • From first dose through 28 days after last dose, up to 40 weeks.
Respiratory, thoracic and mediastinal disorders
Dysphonia
16.7%
1/6 • From first dose through 28 days after last dose, up to 40 weeks.
Respiratory, thoracic and mediastinal disorders
Epistaxis
16.7%
1/6 • From first dose through 28 days after last dose, up to 40 weeks.
Respiratory, thoracic and mediastinal disorders
Laryngeal pain
16.7%
1/6 • From first dose through 28 days after last dose, up to 40 weeks.
Skin and subcutaneous tissue disorders
Alopecia
16.7%
1/6 • From first dose through 28 days after last dose, up to 40 weeks.
Skin and subcutaneous tissue disorders
Decubitus ulcer
16.7%
1/6 • From first dose through 28 days after last dose, up to 40 weeks.
Skin and subcutaneous tissue disorders
Palmar-plantar erythrodysaesthesia syndrome
16.7%
1/6 • From first dose through 28 days after last dose, up to 40 weeks.
Skin and subcutaneous tissue disorders
Rash
50.0%
3/6 • From first dose through 28 days after last dose, up to 40 weeks.
Skin and subcutaneous tissue disorders
Skin fissures
16.7%
1/6 • From first dose through 28 days after last dose, up to 40 weeks.
Vascular disorders
Vasculitis
16.7%
1/6 • From first dose through 28 days after last dose, up to 40 weeks.

Additional Information

Senior Director, Clinical Operations

Puma Biotechnology, Inc.

Phone: +1 (424) 248-6500

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place

Restriction type: LTE60